Mizoram University Researchers Identify Repurposed Drug Targets for COVID-19

Mizoram University Researchers Identify Repurpose Drug Targets for COVID-19

A research team from Mizoram University from northwestern India recently published the results of a study titled, ‘Step toward repurposing drug discovery for COVID-19 therapeutics through in silico approach.” Funded by the Indian government’s Ministry of Science and Technology (Department of Biotechnology), the group remind all of the devastating health and economic consequences of the COVID-19 pandemic, declaring that no effective vaccine or therapy is yet available, despite an intensive past ten months of drug discovery and development efforts. As seen from one point of view (e.g. that the average therapy takes many years of research and development) it's actually amazing what the pharmaceutical industry, government agencies, and academic researchers have pulled off, including one approved therapy (remdesivir), two therapies available via emergency use authorization (Lilly’s monoclonal antibody and convalescent plasma), and the finding that dexamethasone can reduce death rates in certain severe cases. Moreover, based on interim data, Pfizer and BioNTech recently declared that their experimental vaccine showed great promise.  However, viewed from another lens, this isn’t enough a...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee